Posts

Viral clearance studies are part of a multifaceted approach to ensure biopharmaceutical product safety. To prevent costly changes to a manufacturing process, it is important to assess each operation unit for its efficiency early on during downstream process development. See how a design of experiments (DOE) approach was utilized in this case study to investigate the effect of buffer pH and conductivity on the removal of impurities by an anion exchange (AEX) mixed-mode chromatography resin.

In this webinar, see how a Bio-Plex Pro Assay could provide a high-throughput culture-free NT50 determination method for current and future SARS-CoV-2 variants.

Christien Bowman, MSc, has traversed a path from psychology to neuroscience, and is now working on attaining his PhD in biomedicine. In this interview, we discussed how Bowman uses Chelex 100 Resin as part of a fast and cost-effective method to determine the sex of zebra finch songbirds. This work ultimately helps Bowman study a behavioral paradigm that creates autism-like features in songbirds.

When it comes to tumor profiling, the poor quality and degradation of RNA in formalin-fixed paraffin-embedded (FFPE) samples are major limitations. To overcome this challenge, we tested a novel RNA-Seq workflow using the SEQuoia Complete Library Prep Kit and the SEQuoia Ribodepletion Kit. This workflow offers more complex transcriptome profiling, including both long and short RNA biotypes, to better represent the complete transcriptome.

Chimeric antigen receptor (CAR) T cells represent the next generation of therapeutic interventions and are a major advancement in personalized disease treatment. CAR T-cell therapies utilize a patient’s own T cells to recognize and destroy cancer cells or other disease-causing cells. Find out how the ZE5 Cell Analyzer has helped overcome some of the challenges associated with development of these powerful new therapies.

Large-scale downstream processing of viruses can face a range of obstacles different from those of many biotherapeutics. These challenges mostly arise from the size and complexity of the virus, which can affect product purity and recovery. Improvements of purification tools are necessary to overcome these challenges and must be engineered for easy scalability to meet manufacturing demands. In this video, Dr. Mark Snyder discusses common difficulties when developing purification strategies for vaccine production and gene therapy.

Learn how to improve your western blotting results with our Quick Tips video series. Watch these 1–2 minute videos see how to perfect each step of the western blotting process.

Historically, five-year survival rates have been used to evaluate cancer therapeutic effectiveness in clinical trials. But time is critical for research — and for patients. Fortunately, there is a promising method for evaluating cancer therapeutic effectiveness that could potentially offer prognostic insights after just one year. Noninvasive liquid biopsy analysis, including analysis of circulating tumor DNA, is improving researchers’ ability to detect clinical responses more rapidly.

Carter Mitchell, PhD, is a protein problem solver. As Chief Science Officer at Kemp Proteins, he helps academic and industry researchers develop a range of protein therapeutics, diagnostics, and molecular tools in milligram to gram quantities with bioprocess scale in mind. In this interview, we discussed how Kemp Proteins ensures delivery of high-quality processes and protein-based products to their clients, even when working with difficult proteins.

Current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have reduced the severity of the coronavirus disease 2019 (COVID-19). However, the drastic and quick evolution of the virus poses challenges to the development of durable and efficacious therapeutics for vaccine and antibody developers alike. See how the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit speeds up the qualitative measurement of neutralizing antibodies (NAbs) against new SARS-CoV-2 variants, removing a roadblock in COVID-19 therapeutic development.